Overview
MOTS-c is a 16 amino acid peptide encoded in the mitochondrial genome. In rodent and human research it acts as a signal from the mitochondria to the rest of the cell, influencing how cells use glucose and respond to exercise.
There are no canine pharmacokinetic or clinical studies yet. MOTS-c is not a first-line option. It is prescribed by exception, inside a valid VCPR, with documented owner consent and baseline bloodwork.
Mechanism of action
- 01Activates AMPK, a central regulator of cellular energy balance, in preclinical models.
- 02Influences folate cycle and purine metabolism, which shapes how cells handle energy stress.
- 03Expression rises with exercise in human and rodent studies.
- 04Studied in rodents for insulin sensitivity and age-related decline in physical capacity.
Molecular data
Species
Dog
Emerging. No canine pharmacokinetic or clinical data. Considered only for metabolic support cases where conventional options are not appropriate, with owner consent and baseline chemistry and fasting glucose.
Cat
Excluded. There are no feline data, and MOTS-c is not prescribed for cats on this platform.
Prescribing indications
- MetabolicEmergingMetabolic support adjunct in dogs, prescribed by exception.
- RecoveryEmergingExercise tolerance support under veterinary monitoring.
Dosing and administration
Starting, maintenance, and loading doses are calculated in the platform for the patient’s weight band, at the vial strength our compounding partner dispenses, and drawn to U-100 syringe units for the client’s dosing card. Any override is logged with your initials.
See the worked dose exampleScreening and safety
Screen first
Owner consent and baseline bloodwork. Not for cats, pregnancy, or lactation
Follow up
Baseline bloodwork, body condition score, and exercise tolerance. Measure at baseline and recheck at 4 to 6 weeks with the same measure.
The most speculative peptide we offer. No canine safety data exist. Not for pregnant or lactating animals. Use caution in diabetic patients and in animals with a prior adverse drug reaction. Cats are excluded.
References
Related
MOTS-c is consent-gated. It is prescribed only after documented owner consent and baseline bloodwork, as a patient-specific compounded prescription under FDA GFI 256.
This monograph describes a compounded veterinary medication available by prescription only through a licensed veterinarian inside an active veterinarian-client-patient relationship. Not FDA-approved for animal or human use. Compounded on a patient-specific basis under FDA Guidance for Industry #256. For educational use by licensed veterinarians. Not intended for consumer self-prescribing.